Combined pegylated liposomal doxorubicin and bortezomib is
highly effective in patients with recurrent or refractory
multiple myeloma who received prior thalidomide/lenalidomide
therapy.

J 2008

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.

SONNEVELD, P., Roman HÁJEK, A NAGLER, A SPENCER, J BLADÉ et. al.

Basic information

Original name

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.

Name in Czech

Kombinace liposomálního doxorubicinu a bortezomibu je efektivnější u pacientů s refrakterním mnohočetným myelomem předléčených thlaidomidem/lenalidomidem

Authors

SONNEVELD, P., Roman HÁJEK, A NAGLER, A SPENCER, J BLADÉ, T ROBAK, SH ZHUANG, JL HAROUSSEAU and R ORLOWSKI

Edition

Cancer, United States, Wiley, 2008, 0008-543X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 5.238

Organization unit

Faculty of Medicine

UT WoS

000254317300013

Keywords (in Czech)

mnohočetný myelom;doxorubicin;bortezomib

Keywords in English

multiple myeloma;doxorubicin;bortezomib

Abstract

ORIG CZ

V originále

Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma. (MM). In the current analysis, they determined 1) the efficacy of PLD plus bortezomib versus bortezomib alone in patients with MM who had failed on prior thalidomide/lenalidomide (immunomodulatory drug [IMiD]) treatment and 2) the efficacy and safety profile of PLD plus bortezomib in IMiD-exposed and IMiD-naive patients.

In Czech

Autoři článku popisují výsledky studie, v níž byl pacientům s mnohočetným myelomem podáván bortezomib v kombinaci s liposomálním doxorubicinem.

Citovat

SONNEVELD, P., Roman HÁJEK, A NAGLER, A SPENCER, J BLADÉ, T ROBAK, SH ZHUANG, JL HAROUSSEAU and R ORLOWSKI. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer. United States: Wiley, 2008, vol. 112, No 7, p. 1529-1537. ISSN 0008-543X.

@article{817666,
   author = {Sonneveld, P. and Hájek, Roman and Nagler, A and Spencer, A and Bladé, J and Robak, T and Zhuang, SH and Harousseau, JL and Orlowski, R},
   article_location = {United States},
   article_number = {7},
   keywords = {multiple myeloma;doxorubicin;bortezomib},
   language = {eng},
   issn = {0008-543X},
   journal = {Cancer},
   title = {Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.},
   volume = {112},
   year = {2008}
}

TY  - JOUR
ID  - 817666
AU  - Sonneveld, P. - Hájek, Roman - Nagler, A - Spencer, A - Bladé, J - Robak, T - Zhuang, SH - Harousseau, JL - Orlowski, R
PY  - 2008
TI  - Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
JF  - Cancer
VL  - 112
IS  - 7
SP  - 1529-1537
EP  - 1529-1537
PB  - Wiley
SN  - 0008543X
KW  - multiple myeloma;doxorubicin;bortezomib
N2  - Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma. (MM). In the current analysis, they determined 1) the efficacy of PLD plus bortezomib versus bortezomib alone in patients with MM who had failed on prior thalidomide/lenalidomide (immunomodulatory drug [IMiD]) treatment and 2) the efficacy and safety profile of PLD plus bortezomib in IMiD-exposed and IMiD-naive patients.
ER  -

SONNEVELD, P., Roman HÁJEK, A NAGLER, A SPENCER, J BLADÉ, T ROBAK, SH ZHUANG, JL HAROUSSEAU and R ORLOWSKI. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. \textit{Cancer}. United States: Wiley, 2008, vol.~112, No~7, p.~1529-1537. ISSN~0008-543X.

Detailed Information on Publication Record